Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.69 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.66 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.56 |
| ▸ | CXCR1 | P25024 | 4/20 | 0.56 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.56 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2060445 | 0.86 | PTGS2 (0.54) | PTGS2AKR1C3AKR1C2PTGS1CXCR1 | |
| SCHEMBL9425565 | 0.86 | PTGS2 (0.56) | PTGS2AKR1C3AKR1C2PTGS1CXCR1 | |
| SCHEMBL4682035 | 0.84 | PTGS2 (0.51) | PTGS2AKR1C3AKR1C2PTGS1CXCR1 | |
| SCHEMBL4682033 | 0.84 | PTGS2 (0.51) | PTGS2AKR1C3AKR1C2PTGS1CXCR1 | |
| SCHEMBL2319534 | 0.84 | PTGS2 (0.58) | PTGS2AKR1C3AKR1C2PTGS1CXCR1 | |
| SCHEMBL1345158 | 0.84 | PTGS2 (0.64) | PTGS2AKR1C3AKR1C2PTGS1CXCR1 | |
| SCHEMBL3242802 | 0.84 | PTGS2 (0.54) | PTGS2AKR1C3AKR1C2PTGS1CXCR1 | |
| SCHEMBL2391075 | 0.84 | PTGS2 (0.54) | PTGS2AKR1C3AKR1C2PTGS1CXCR1 | |
| SCHEMBL66533 | 0.84 | PTGS2 (0.64) | PTGS2AKR1C3AKR1C2PTGS1CXCR1 | |
| SCHEMBL6903957 | 0.84 | PTGS2 (0.58) | PTGS2AKR1C3AKR1C2PTGS1CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714240-B2 | Vinyl autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170066751-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2017-03-09 | — | — | US | disclosed |
| EP-3021879-A2 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH | Cayman Chemical Company, Incorporated (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-2875022-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2015-05-27 | — | — | EP | disclosed |
| EP-2874620-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2015-05-27 | — | — | EP | disclosed |
| WO-2015009991-A2 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH | CAYMAN CHEMICAL COMPANY, INC. (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2014015246-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2014015247-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | PTGS2 3523/4885AKR1C3 809/4885AKR1C2 844/4885 |
| US-20170066751-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | PTGS2 63/4885AKR1C3 1369/4885AKR1C2 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.